国产替罗非班治疗急性冠状动脉综合征的临床研究Efficacy and safety of tirofiban in patients with acute coronary syndrome undergoing percutaneous coronary intervention
侯玉清,周忠江,黎建勇,贾满盈,吴平生,刘伊丽,滕中华
摘要(Abstract)：
目的在常规抗凝、抗血小板基础上,观察国产血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班治疗急性冠状动脉(冠脉)综合征的疗效和安全性。方法本试验为随机、双盲、安慰剂平行对照临床研究。符合急性冠脉综合征(不稳定型心绞痛/非Q波心肌梗死)入选标准患者62例,按就诊顺序双盲随机分为受试组(替罗非班,n=32)和对照组(n=30)。在均使用阿司匹林、氯吡格雷和肝素的基础上,试验组给予替罗非班(负荷量10μg/kg,在3min内推注),继以0.15μg/(kg.min)由微量泵持续泵入24~36h;对照组病例直接进行经皮冠状动脉介入治疗(PCI)。结果试验组30d内主要不良心脏事件(MACE,包括顽固性心绞痛/新发心肌梗死/死亡)发生率较对照组显著降低(9.3%比20.0%,P<0.05),心电图ST段下移程度和缺血导联数明显减少(P<0.05)。围术期出血并发症较对照组稍高,但差异无统计学意义。两组术后血小板计数、心功能(射血分数值)差异无统计学意义。结论国产替罗非班在急性冠脉综合征标准治疗基础上能进一步减少心肌缺血事件发生率,改善心电图心肌缺血改变,安全性好,但其长期疗效及毒副作用有待进一步观察。
关键词(KeyWords)： 冠状动脉疾病;替罗非班;治疗结果
基金项目(Foundation):
作者(Author): 侯玉清,周忠江,黎建勇,贾满盈,吴平生,刘伊丽,滕中华
参考文献(References)：
- [1]Kimmelstiel C,Badar J,Covic L,et al.Pharmacodynamics and pharmacokinetics of the platelet GPⅡb/Ⅲa inhibitor tirofiban in patients undergoing percutaneous coronary intervention:implications for adjustment of tirofiban and clopidogrel dosage.Thromb Res,2005,116:55-66.
- [2]Ernst NM,Suryapranata H,Miedema K,et al.Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction.J Am Coll Cardiol,2004,44:1187-1193.
- [3]Morrow DA,Sabatine MS,Antman EM,et al.Usefulness of tirofiban among patients treated without percutaneous coronary intervention(TIMI high risk patients in PRISM-PLUS).Am J Cardiol,2004,94:774-776.
- [4]Valgimigli M,Percoco G,Barbieri D,et al.The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty:the ADVANCE Trial.J Am Coll Cardiol,2004,44:14-19.
- [5]Wyss CA,Roffi M.Platelet Inhibition in Percutaneous Coronary Interventions.Herz,2005,30:189-196.
- [6]The PRISM-PLUS investigators.Inhibition of the platelet glycoproteinⅡb/Ⅲa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.N Engl J Med,1998,338:1488.
- [7]The PRISM investigators.A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.N Engl J Med,1998,338:1498.
- [8]Gibson CM,Dotani MI,Murphy SA,et al.Correlates of coronary blood flow before and after percutaneous coronary intervention and their relationship to angiographic and clinical outcomes in the RESTORE trial.Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.Am Heart J,2002,144:130-135.